Riociguat - the first proven effective pharmacotherapy in patients with unresectable and residual chronic thromboembolic pulmonary hypertension

Abstract

Chronic thromboembolic pulmonary hypertension (CTEPH) is a chronic due to acute pulmonary embolism in patients who do not occur to dissolve the embolized thrombotic mass when thrombolytic and / or anticoagulant therapy .

Keywords

• Riociguat
• pharmacotherapy
• inoperable
• residual
• Chronic thromboembolic pulmonary hypertension